P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE

• V. Bücklein,
• A. Perez,
• G. Iacoboni,
• K. Rejeski,
• U. Holtick,
• O. Penack,
• S. Kharboutli,
• V. Blumenberg,
• J. Ackermann,
• L. Frölich,
• G. Johnson,
• K. Patel,
• B. Arciola,
• C. Schmidt,
• O. Albanyan,
• P. Gödel,
• E. Hoster,
• L. Bullinger,
• A. Mackensen,
• F. Locke,
• M. von Bergwelt,
• P. Barba,
• M. D. Jain,
• M. Subklewe

Affiliations

V. Bücklein

1 Department of Medicine III, University Hospital, University of Munich

A. Perez

3 Blood & Marrow Transplant Program, Miami Cancer Institute, Miami

G. Iacoboni

5 Department of Hematology, University Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Department of Medicine, Universitat Autònoma of Barcelona (UAB), Barcelona, Spain

K. Rejeski

1 Department of Medicine III, University Hospital, University of Munich

U. Holtick

7 Department I of Internal Medicine, Medical Faculty and University Hospital, Cologne

O. Penack

8 Medical Clinic, Department for Haematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin

S. Kharboutli

9 Department of Internal Medicine 5, Hematology and Oncology, University of Erlangen-Nuremberg, Erlangen, Germany

V. Blumenberg

1 Department of Medicine III, University Hospital, University of Munich

J. Ackermann

1 Department of Medicine III, University Hospital, University of Munich

L. Frölich

1 Department of Medicine III, University Hospital, University of Munich

G. Johnson

10 USF Health Morsani College of Medicine, Tampa, United States of America

K. Patel

10 USF Health Morsani College of Medicine, Tampa, United States of America

B. Arciola

10 USF Health Morsani College of Medicine, Tampa, United States of America

C. Schmidt

1 Department of Medicine III, University Hospital, University of Munich

O. Albanyan

4 Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, United States of America

P. Gödel

7 Department I of Internal Medicine, Medical Faculty and University Hospital, Cologne

E. Hoster

11 Institute for Medical Information Processing, Biometry, and Epidemiology, LMU Munich, Munich, Germany

L. Bullinger

8 Medical Clinic, Department for Haematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin

A. Mackensen

9 Department of Internal Medicine 5, Hematology and Oncology, University of Erlangen-Nuremberg, Erlangen, Germany

F. Locke

4 Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, United States of America

M. von Bergwelt

1 Department of Medicine III, University Hospital, University of Munich

P. Barba

5 Department of Hematology, University Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Department of Medicine, Universitat Autònoma of Barcelona (UAB), Barcelona, Spain

M. D. Jain

4 Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, United States of America

M. Subklewe

1 Department of Medicine III, University Hospital, University of Munich